CD8A and neoplasm: Pembrolizumab, an anti‐programmed death‐1 (PD‐1) antibody, enhances anti‐tumor cytotoxicity of T lymphocytes (CD8+T cells) through blockade of PD‐1 immune checkpoint signaling.26